RecruitingPhase 1Phase 2NCT06725758
A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours
Sponsor
Orion Corporation, Orion Pharma
Enrollment
315 participants
Start Date
Oct 26, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
Multi-site, open-label, first-in-human study with 2 parts (dose escalation and dose expansion) in subjects with selected advanced solid tumours
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called ODM-212 for people with solid tumours. The study is currently recruiting participants at 20 locations. People eligible for this study include aged 18 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGODM-212
ODM-212 5mg and/or 40mg tablets
Locations(20)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06725758
Related Trials
A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors
NCT0716072519 locations
A Study of BI 3810944 in Patients With Advanced Cancer
NCT072244257 locations
Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations
NCT0658143290 locations
Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours
NCT0744685519 locations
A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab
NCT0739167019 locations